Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis

Abstract

In this uncontrolled trial, administration of exogenous AP enzyme daily over a 7-day course to patients with UC was associated with short-term improvement in disease activity scores, with clinical effects being observed within 21 days and associated with reductions in C-reactive protein and stool calprotectin. AP enzyme treatment was well tolerated and nonimmunogenic.

Intestinal alkaline phosphatase promotes gut bacterial growth by reducing the concentration of luminal nucleotide triphosphates

“…Pharmacologically, IAP has been found to be an effective therapy against various human as well as animal disease models including IBD, necrotizing enterocolitis, gram-negative sepsis, C. difficile, and S. typhimurium infections, and metabolic syndrome (1,21,34,44,56,58,61). Clinical trials using bovine IAP against colitis have shown that IAP has no or minimal side effects (34).…”

Intestinal alkaline phosphatase inhibits the proinflammatory nucleotide uridine diphosphate

“…In acute (9,42) and chronic (35) rodent models of colitis, exogenous administration of IAP significantly reduced colonic inflammation, and Campbell et al (10) induced and inhibited endogenous IAP activity in mice with dextran sodium sulfate-induced colitis and showed that disease severity negatively correlated with IAP activity. Additionally, in the first report of IAP for human IBD, Lukas et al (27) showed that intraduodenal administration of IAP in 21 patients with refractory ulcerative colitis resulted in significant improvement in several objective disease parameters. Importantly, IAP was associated with no significant side effects (27), unlike nearly every other treatment available for IBD (33).…”

“…Additionally, in the first report of IAP for human IBD, Lukas et al (27) showed that intraduodenal administration of IAP in 21 patients with refractory ulcerative colitis resulted in significant improvement in several objective disease parameters. Importantly, IAP was associated with no significant side effects (27), unlike nearly every other treatment available for IBD (33). Taken together, these studies indicate a protective role for endogenous and exogenous IAP against colitis.…”

“…Exogenous IAP has been shown to be a potential treatment in human ulcerative colitis (27) and in several animal models of IBD. Although IAP has clear anti-inflammatory properties in a variety of bacteria-induced gastrointestinal diseases, its precise mechanism of action is unclear.…”

The role of intestinal alkaline phosphatase in pediatric inflammatory bowel and celiac diseases

“…COD-ben mind a veleszületett, mind a szerzett immunitásnak szerepe van [39]. A COD prevalenciája a legtöbb országban 1% körül mozog, és a HLA DQ2 gének iránti fogékonyság 20%-os, a HLA DQ8 iránt pedig 80%-os a kaukázusi népcsoportban [40], vagyis a specifi citás igen alacsony.…”